Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rQNestin34.5v.2 With or Without Cyclophosphamide in Recurrent Malignant Glioma
NCT03152318Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2017
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of CAN-3110 in malignant glioma (3 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Jul 2017; status: active, not recruiting.
02
Drugs
CAN-3110
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT03152318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03152318.